Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048620 · ClinicalTrials.gov registry record · Phase 1
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
A Phase 1 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00048620 is a Phase 1 study that has completed, run by BioMarin Pharmaceutical.
The verdict
NCT00048620, a Phase 1 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.
Interventions
- DRUG N-acetylgalactosamine 4-sulfatase
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048620
The ClinicalTrials.gov registry entry for NCT00048620 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetylgalactosamine 4-sulfatase is the first listed.
NCT00048620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048620 about?
NCT00048620 is a clinical study titled "Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI". The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.
What is the current status of trial NCT00048620?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-09. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00048620?
The interventions under investigation include: N-acetylgalactosamine 4-sulfatase (DRUG).
Who is sponsoring clinical trial NCT00048620?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.